enEN
ptPT

Innovation

RPH GROUP is in continuous development, with its Innovation team, in search of new products and procedures for Brazilian’s Nuclear Medicine growth.

This business format will allow our partners to access firsthand innovations. Currently, RPH Group’s sales pipeline counts on diverse radiopharmaceuticals in development, most of them not available in the country yet.

Through its cold kits factory and central radiopharmacies network, RPH Group will offer to its partners a greater range of products and services with high quality.

RESEARCHES AND INNOVATIONS IN NUCLEAR MEDICINE

Studies and development of new molecules

HYNIC-PSMA-Tc-99m

Promising tool that will assist the detection of metastatic lymph nodes in patients with primary prostate cancer or biochemical relapse.

PSMA One Step and DOTATOC One Step

Diagnosis of prostate cancer relapse and neuroendocrine tumors, respectively.

Reduced preparation time, lower manipulator’s dependence, no need to have special and expensive equipment.

FAPI-Ga-68

Protein binder of activation fibroblast, superexpressed in several kinds of cancers promising results in the detection of 28 kinds of cancers.

PSMA Ac-255

The treatment with PSMA Ac-255 presented impressive results in patients with metastatic prostate cancer.

Rhenium-SCT

Innovative treatment for Non-Melanoma Skin Cancer using the betatherapy with RE-188.

Menu